慢性充血性心力衰竭患者血浆miR-423-5p和miR-210-3p的表达变化

The expression changes of plasma miR-423-5p and miR-210-3p in patients with chronic heart failure

目的：探讨血浆miR-423-5p和miR-210-3p在慢性充血性心力衰竭（CHF）患者中的表达及意义。方法：采用实时荧光定量PCR（RT-PCR）技术检测30例CHF患者（CHF组）治疗前后及30例健康体检者（对照组）血浆中miR-423-5p和miR-210-3p的表达水平,并分析其与临床特征之间的关系;运用ROC曲线评价其在CHF诊断中的潜在价值。结果：CHF组血浆miR-423-5p表达量较对照组升高,差异具有统计学意义（P〈0.05）。CHF组治疗前血浆miR-423-5p与N末端B型脑钠肽前体（NT-proBNP）、左室舒张末期内径（LVEDD）存在正相关性（r=0.432、0.386,均P〈0.05）。CHF组治疗后血浆miR-423-5p和miR-210-3p表达水平均较治疗前降低,均差异有统计学意义（均P〈0.05）;且治疗后miR-423-5p与NT-proBNP存在正相关性（r=0.372,P=0.043）。miR-423-5p ROC曲线下面积为0.916（95%CI：0.845～0.988）,灵敏度和特异度分别为83.3%和90.0%;miR-210-3p ROC曲线下面积为0.778（95%CI：0.654～0.901）,灵敏度和特异度分别为76.7%和73.3%。结论：CHF患者血浆miR-423-5p和miR-210-3p表达升高,随着心功能好转,其表达水平降低,有望成为CHF诊断及预后的生物学标志物。

Objective：To explore the expression of plasma miR-423-5p and miR-210-3p in patients with chronic heart failure （CHF） and clinical significance. Method：We measured the concentrations of plasma miR-423-5p and miR-210-3p before and after treatment in 30 CHF cases and 30 controls by real-time PCR wih U6 as internal con- trol, and analyzed the possible correlation between miR-423-5p and miR-210-3p and clinical features, and assessed their value in diagnosis of CHF by using ROC curve. Result：The expression of plasma miR-423-5p and miR-210-3p were significantly greater in CHF group（P〈0.05）, the level of miR-423-5p was correlated with NT-proBNP and LVEDD （r= 0. 432,0. 386 respectively;both P〈0.05）. The expression of miR-423-5p and miR-2]0-3p decreased in CHF patients after treatment compared with before （P〈0. 05）, and there was a positive correlation between miR-423-5p and NT-proBNP （r=0. 372,P〈0. 043） after treatment. For miR-423-Sp,the area of ROC curve was 0. 916（95%CI： 0. 845-0. 988）, and sensitivity and specificity were 83.3% and 90%;For miR-210-3p, the area of ROC curve was 0. 778（95%CI： 0. 654-0. 901）, and sensitivity and specificity were 76.7% and 73.3%. Conclu- sion：The expression of plasma miR-423-5p and miR-210-3p are up-regulated in CHF and they decrease after treat- ment. MiR-423-5p and miR-210-3p could be the biomarkers in diagnosis of CHF.